Julius Clinical

Julius Clinical The science CRO. We combine strong scientific leadership and operational excellence to conduct innov At Julius Clinical, science is the foundation.

Combined with flexibility, creativity, and innovation our scientific approach enables fast, efficient, and high quality ex*****on of complex clinical development programs. Our skilled and loyal networks of investigators all around the world allow us to offer superior recruitment in therapeutic area’s such as cardiology, diabetes, CNS and infectious diseases. Our partners include leading pharmaceutical, biotech, medical device, and food companies, as well as academic investigators and research consortia. We focus on clinical trials likely to have a major impact on the practice of medicine and patient outcomes. This demanding research requires more than a ‘one-size-fits-all’ approach, and our fusion of scientific and operational expertise enables delivery of results efficiently, on time and budget. Julius Clinical employs internationally recognized academic leaders who are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and influence, combined with personal links with peers around the world, provides a truly global reach and reputation. Julius Clinical has completed over 50 investigator-initiated and industry-sponsored trials, enrolling over 130.000 patients across 30 countries worldwide, involving innovative pharmaceuticals in a broad range of therapeutic areas, including infectious diseases, cardiovascular and metabolic
diseases, and central nervous system (CNS) diseases. Through our global networks we can quickly select the most appropriate and
highest-performing sites to take part in a trial and ensure that investigators are inspired
and motivated. We currently have a cardiology network of about 1000 sites, about 500 general internal medicine and 2000 general practitioners. Julius Clinical was
incorporated in 2008 and is affiliated with the Julius Center for Health Sciences and Primary Care at the University Medical Center Utrecht, the Netherlands. We are dedicated to operational and academic excellence. We are Julius Clinical. Please contact us for more information.

Real-World Evidence in Medicine Development: an online introductory courseWe are pleased to announce that enrollment for...
04/07/2018

Real-World Evidence in Medicine Development: an online introductory course
We are pleased to announce that enrollment for the third edition of the course is now open. The course will run from Sept. 3 – Oct. 26, 2018. Visit www.imi-getreal.eu for more information and enrollment.

Julius Centrum - IMI GetReal - Real-Life Data In Drug Development

Real-World Evidence in Medicine Development: an online introductory courseWe are pleased to announce that enrollment for...
04/07/2018

Real-World Evidence in Medicine Development: an online introductory course

We are pleased to announce that enrollment for the third edition of the course is now open. The course will run from Sept. 3 – Oct. 26, 2018. Visit www.imi-getreal.eu for more information and enrollment.

Julius Centrum - IMI GetReal - Real-Life Data In Drug Development

Have a look at our new corporate brochure to find out more about what we do.
08/06/2018

Have a look at our new corporate brochure to find out more about what we do.

25/01/2017

JULIUS CLINICAL FORMS ALLIANCE WITH PAREXEL
Alliance aims to strengthen global clinical trial services by aligning scientific and operational aspects of clinical trials.

Full statement --> https://www.juliusclinical.com/news/julius-clinical-forms-alliance-parexel

Alliance aims to strengthen global clinical trial services by aligning scientific and operational aspects of clinical trials

LIVE WEBINAR “BESTAAN NIET-ERNSTIGE HYPO’S?”Woensdag 25 januari 2017 20.30 - 21.15 uurOp woensdag 25 januari vindt een w...
12/01/2017

LIVE WEBINAR “BESTAAN NIET-ERNSTIGE HYPO’S?”
Woensdag 25 januari 2017 20.30 - 21.15 uur

Op woensdag 25 januari vindt een webinar plaats met als centraal onderwerp 'Niet-ernstige hypo’s in de dagelijkse praktijk'. Resultaten uit de door het PCRN uitgevoerde HAT studie maken deel uit van deze webinar. Vanuit Julius Clinical zal Dr. Catherine Enters-Weijnen een toelichting geven op de bevindingen.

Gemiddeld blijkt een diabetespatiënt twee niet-ernstige hypo’s per week te hebben. Nel Geelhoed (internist, Haaglanden Medisch Centrum): “Wat dus kan betekenen dat sommigen er nooit eentje hebben, en anderen tien. Zo’n groot aantal heeft impact op je kwaliteit van leven.”

Na het volgen van deze webinar weet u hoe groot de kans op hypo’s is en wat de achterliggende oorzaken kunnen zijn.
U krijgt onder andere antwoord op de volgende vragen:

- Hoe groot is de kans op hypo’s en wat zijn de achterliggende oorzaken?
- Heeft het HbA1c - niveau een voorspellende waarde op het krijgen van hypo’s?
- Waarom heeft de één meer klachten dan de ander?

Datum
Reserveer vast 25 januari 2017 in uw agenda, deelname is kosteloos.

Sprekers
dr. Nel Geelhoed-Duijvestijn, internist, Haaglanden Medisch Centrum
dr. Catherine Enters-Weijnen, Associate Director Primary Care Research, Julius Clinical
Martin Voerknecht, huisarts, Medisch Centrum Bussum Zuid

Aanmelden en deelnemen
Klik op de onderstaande link om u voor de webinar aan te melden.

Voor wie?
Huisartsen, praktijkondersteuners/-verpleegkundigen en diabetesverpleegkundigen

Accreditatie
Toegekend door ABC-1 (CvAH), VSR, Kwaliteitsregister V&V, NVvPO (1 pnt); aangevraagd voor 1 punt bij EADV

Woensdag 25 januari 2017, 20:30:00. Accreditatie Toegekend door ABC-1 (CvAH), VSR, Kwaliteitsregister V&V, NVvPO (1 pnt); aangevraagd voor 1 punt bij EADV Aanmelden Klik op de knop Aanmelden om u voor dit webinar aan te melden. Deelnemen Klik op de knop Open webinar om de webinar player te openen. I...

Julius Clinical's chief scientist Rick Grobbee receives €20 million grant for innovative cardiovascular research BigData...
08/12/2016

Julius Clinical's chief scientist Rick Grobbee receives €20 million grant for innovative cardiovascular research BigData@Heart at UMC Utrecht.


http://www.umcutrecht.nl/en/Research/News/UMC-Utrecht-receives-%E2%82%AC20-million-for-big-data-rese

In the UMC Utrecht research is concentrated in six programs with each a limited number of disease targets. Patient care is integrated in these programs. A relentless multidisciplinary approach guarantees patients benefit from the latest available expertise and innovative technological solutions. Int...

"The development of the next generation of Alzheimer’s disease treatments is among the most important health needs world...
06/12/2016

"The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges."

Julius Clincial can and wants to help tackle those challenges. This is why Paul van Meurs, MD. will attent and be available for meetings at the 9th Clinical Trials on Alzheimer's disease (CTAD) conference, Dec. 8-10, 2016 in San Diego. We hope to see you there.

http://www.ctad-alzheimer.com/ Alzheimer's Association Alzheimer Nederland

Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge.

22/11/2016

Andre Smorenburg, Tim Vaessen en Tom Dijks hebben hun Black Belt certificaat in de wacht gesleept. De drie heren hebben het examen met een ruime voldoende gehaald én hebben in hun werk bij Julius Clinical aangetoond Six Sigma echt te beheersen. Ze hebben op basis van een sterke data-analyse de proce...

Former Quintiles Global VP of the Cardiovascular Therapeutic Unit, Hans van Dijk, appointed COO of Dutch science CRO, Ju...
22/11/2016

Former Quintiles Global VP of the Cardiovascular Therapeutic Unit, Hans van Dijk, appointed COO of Dutch science CRO, Julius Clinical.

Click link to read full statement --> https://www.juliusclinical.com/news/julius-clinical-appoints-new-coo-0

ZEIST — November 21st, 2016 — Julius Clinical Board of Directors is pleased to announce that Hans van Dijk, former Quintiles Global VP of the Cardiovascular Therapeutic Unit and former Global Head of Regulatory and Start-up, will join the company as its new Chief Operating Officer. Van Dijk will suc...

Did you see this? The new Julius Clinical ad premiered in the Partnerships in Clinical Trials event guide.
17/11/2016

Did you see this? The new Julius Clinical ad premiered in the Partnerships in Clinical Trials event guide.

Adres

41-43 Broederplein
Zeist
3703CD

Openingstijden

Maandag 09:00 - 17:30
Dinsdag 09:00 - 17:30
Woensdag 09:00 - 17:30
Donderdag 09:00 - 17:30
Vrijdag 09:00 - 17:30

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Julius Clinical nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Delen

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

We start with science in mind and combine that with unsurpassed operational implementation to create bold and imaginative solutions for our clients - solutions that are unique and tailor-made for each study. We are the research organisation that is able to combine the latest scientific insights with operational excellence to find credible, creative, cost-effective solutions for clinical trials. • We have a strong and committed network of academic leaders and investigators around the world in a variety of therapeutic areas. • We are partners with key medical centers, academic leaders, and investigators which ensure commitment and adherence to study guidelines of local clinicians all around the world. • We have access to sites and eligible patients for clinical trials. • We offer the peer-to-peer leadership model: enhanced recruitment and retention through leadership of investigators in our networks.

Our internationally recognised academic leaders are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility combined with operational excellence means that we are uniquely equipped to assist in providing answers for today’s clinical drug development challenges. We offer end-to-end CRO services in specific therapeutic areas based on our scientific expertise. But we are also able to manage all aspects of sites – from selection of sites to administration.

We work with independent scientists supporting peer to peer approach of investigators. We closely cooperate with key opinion leaders to support scientific oversight and decide on the optimal operational model. We established international investigator networks to better recruit patients. Our scientists formulate research questions and ideas that we present to a client.

Due to the way we are structured and our willingness to look at innovative solutions, we have the ability and flexibility to react to changes in requirements very quickly. We are able to look beyond process to address the real issues that matter, and work with our site networks and clinical research experts to provide tailor-made, cost effective proposals addressing the needs of Biotech and Pharmaceutical companies, as well as Investigators sponsoring a trial.